Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp Financing Cash Flow

The Net Financing Cash Flow of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Nov 12, 2026 is -284.91 M CNY. In the previous year, Net Financing Cash Flow was -18.73 M CNY — a change of 1,421.46% (lower).

Financing Cash Flow

-284.91 MCNY

YoY

1,421.46%

Last updated:

Net Financing Cash Flow of Vcanbio Cell & Gene Engineering Corp is 2024 -284.91 M CNY. Net Financing Cash Flow of Vcanbio Cell & Gene Engineering Corp was 2023 -18.73 M CNY. It decreases by 1,421.46% lower compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
57.87 M CNY
Jan 1, 2018
-25.43 M CNY
Jan 1, 2019
356.79 M CNY
Jan 1, 2020
-104.96 M CNY
Jan 1, 2021
-49.71 M CNY
Jan 1, 2022
-7.75 M CNY
Jan 1, 2023
-18.73 M CNY
Jan 1, 2024
-284.91 M CNY
The Vcanbio Cell & Gene Engineering Corp Financing Cash Flow history
YEARFinancing Cash FlowYoY
-284.91 MCNY+1,421.46%
-18.73 MCNY+141.67%
-7.75 MCNY-84.41%
-49.71 MCNY-52.64%
-104.96 MCNY-129.42%
356.79 MCNY-1,503.14%
-25.43 MCNY-143.94%
57.87 MCNY-41.28%
98.55 MCNY-62.95%
265.97 MCNY+635.00%
36.19 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp., Ltd. generates revenue through the development and sale of life sciences technology products. The company produces cytokines culture solutions, cosmetics, and detection reagents for domestic markets. Its business segments include cell culture, gene detection and storage, and the production of specialized biological products. The firm's domestic customers primarily purchase these products for research and commercial applications in the life sciences sector. Vcanbio focuses on cell culture and gene detection services, which are integral to its product offerings. The company's cytokines culture solutions are sold to domestic clients in the biotechnology and pharmaceutical industries. Detection reagents are also marketed to domestic laboratories and healthcare providers for diagnostic purposes. The firm leverages its 2,332 full-time employees to support research, development, and production activities. The company's product portfolio includes cosmetics alongside scientific reagents, targeting both consumer and professional markets. Domestic markets remain the primary focus for all sales, with no mention of international operations. Vcanbio's revenue streams are derived from the sale of its core products, which are developed and manufactured in-house. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Net Financing Cash Flow of Vcanbio Cell & Gene Engineering Corp is -284.91 M CNY in 2024.

Net Financing Cash Flow of Vcanbio Cell & Gene Engineering Corp changed from -18.73 M CNY to -284.91 M CNY, representing a 1,421.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Vcanbio Cell & Gene Engineering Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vcanbio Cell & Gene Engineering Corp

All Key Metrics — Vcanbio Cell & Gene Engineering Corp